Ilana Schlam

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 24

Top Topics

Positive Breast Cancer

Locally Advanced

Top Venues

Nature communications

Current oncology reports

OncoTargets and therapy

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Ilana Schlam, Raquel A Nunes, Filipa C Lynce
Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. OncoTargets and therapy 15 (2022)
Jessica P Hwang, Andrew S Artz, Parth D Shah, Banu E Symington, Jordan J Feld, Sarah P Hammond, Emmy Ludwig, Amy Pai, Scott D Ramsey, Ilana Schlam, Jennifer M Suga, Su H Wang, Mark R Somerfield
Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO oncology practice 18 (9) (2022)
Ilana Schlam, Margaret E Gatti-Mays
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. The oncologist 27 (7) (2022)
Ilana Schlam, Paolo Tarantino, Stefania Morganti, Filipa C Lynce, Dario Trapani, Erica L Mayer, Ana Christina Garrido-Castro, Ada Waks, Sara M Tolaney
Emerging Targeted Therapies for Early Breast Cancer. Drugs 82 (14) (2022)
Ilana Schlam, Paolo Tarantino, Sara M Tolaney
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers 14 (16) (2022)
Carolina Bernabe, Ana I Velazquez, Coral Olazagasti, Cristiane Decat Bergerot, Paulo Gustavo Bergerot, José F Corona-Cruz, Ivy Riano, Christina Adaniel, Francisca Ramirez, Jesus D Anampa, Carmen Cajina, Evelin Mena, Elias Gracia, Alvaro Menendez, Henry Idrobo, Raimundo Bezares, Omar Orlando Castillo Fernandez, Liseth Duque, Luis Corrales-Rodríguez, Glenda Ramos, Alba J Kihn-Alarcón, Ilana Schlam, Ximena Jordan Bruno, Gerardo A Umanzor, Jenny Lissette Castro, Federico Losco, Luis Ubillos, Eduardo Richardet, Enrique Soto Pérez de Celis, Narjust Florez, null null
HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America. JCO global oncology 8 (2022)
Filipa C Lynce, Ilana Schlam, Xue Geng, Beth N Peshkin, Sue Friedman, Julie Dutil, Zeina Nahleh, Claudia Campos, Charité Ricker, Patricia Rodriguez, Neelima Denduluri, Jaeil Ahn, Claudine Isaacs, Kristi D Graves
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. Journal of genetic counseling 30 (2) (2020)